Reference drugs for triple combination test drug in Russia [Design Issues]

posted by Yura – Belarus, 2019-11-19 21:51 (335 d 09:07 ago) – Posting: # 20830
Views: 2,932

(edited by mittyri on 2019-11-19 22:50)

Hi Beholder,
There is no reason for the regulator not to want to check section 4.5 of the Guideline on clinical development of fixed combination medicinal products :|>
Kind regards,
Yura


Edit: Guideline linked. Also changed the name in signature to the usual one[Mittyri]

Complete thread:

Activity
 Admin contact
21,164 posts in 4,410 threads, 1,476 registered users;
online 4 (1 registered, 3 guests [including 3 identified bots]).
Forum time: Tuesday 07:59 CEST (Europe/Vienna)

In theory, there is no difference between theory and practice.
But, in practice, there is.    Jan L.A. van de Snepscheut

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5